Pharmacogenomics testing in Addiction Centers helps individualize drug dependence and is performed to optimize treatment efficacy and reduce toxicity and adverse reactions. Pharmacogenomics test the patients’ genetic variation to predict their individualized response to medications which holds much promise to improve treatment of addictive disorders.
The drug categories analyzed by the gene panel for neuropsychiatric include: withdrawal medications, depression, anxiety, psychosis, arthritis and migraine, pain management, and ADHD.
RM Genetics offers programs for Pharmacogenomics testing in Addiction Centers where we help evaluate candidates for pharmacogenomic testing based on clinical applicability of the patients’ profile. We help with program implementation, patient swabbing, laboratory testing, and patient testing results.
Pharmacogenomics Testing in Addiction Centers Will Measure:
Pharmogenomics is increasing adaptation in drug addiction therapy treatments to help over personalized patient care and optimize evolving new treatments. The FDA continues to add more drugs with a pharmacogenomic biomarker as more responders and non-responder of medications are identified.
RM Genetics Offers Complete Program Management and Support
135 E. 57th St., 14th Floor
New York, NY 10022
ABOUT RM GENETICS
At RM Genetics, we strive to work with health providers and facilities to help them offer personalized medical care to their patients and residents. We provide complete program management and support that allows healthcare providers the ability to offer optimal patient care with no inconveniences or added operational requirements. Our Pharmacogenomic testing programs are customized to the patient and resident treatment types and are covered by Medicare and other Health Insurance providers.